Immunological And Clinical Aspects Of Multiple Sclerosis: The Proceedings Of The Xxv Anniversary Symposium Of The Belgian Research Group For Multiple  by R.e. GonsetteImmunological And Clinical Aspects Of Multiple Sclerosis: The Proceedings Of The Xxv Anniversary Symposium Of The Belgian Research Group For Multiple  by R.e. Gonsette

Immunological And Clinical Aspects Of Multiple Sclerosis: The Proceedings Of The Xxv Anniversary…

byR.e. GonsetteEditorP.h. Delmotte

Paperback | February 12, 2012

Pricing and Purchase Info

$143.46 online 
$150.50 list price
Earn 717 plum® points

Prices and offers may vary in store


In stock online

Ships free on orders over $25

Not available in stores


Looking back is a luxury for which scientists normally have little time. This XXV Anniversary Symposium, however, gives the opportunity of reminding us that in Belgium, where the risk of developing multiple sclerosis is among the highest in the world, a great man to whom we all pay tribute, I mean Dr Ludo van Bogaert, in 1957, took the initiative in founding the Belgian Research Group for Multiple Sclerosis. It may sound immodest but since that time members of the Belgian Research Group happen to have an honourable record of important contributions to MS research, quite out of proportion to the financial support they received for it. Indeed, when compared to the situation in English speaking countries, funding of MS research has always been neglected in our country in spite of the fact that in 1958, acting on the advice of the Belgian Research Group, the Belgian National MS Society was founded with the specific object of collecting money for research as well as for social care. At that time, the difficulty in raising funds for research was partly due to the fact that solving the problem of MS appeared almost impossible. Scientists could apparently only too slowly improve their ability to prevent and cure the disease. Media were indifferent to MS which was considered to have no news value, and the public remained uninformed.
Title:Immunological And Clinical Aspects Of Multiple Sclerosis: The Proceedings Of The Xxv Anniversary…Format:PaperbackDimensions:492 pages, 23.5 × 15.5 × 0.17 inPublished:February 12, 2012Publisher:Springer NatureLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:9401163545

ISBN - 13:9789401163545

Look for similar items by category:


Table of Contents

Section I Immunological Aspects of Multiple Sclerosis: Basic Observations.- 1 Auto-immunity.- 2 Occurrence of an internal image of measles haemagglutinin in an anti-idiotype immune response.- 3 Studies on the intrathecal humoral immunity in multiple sclerosis.- 4 Antibody to viral antigens in multiple sclerosis demonstrated by ELISA method.- 5 Cerebrospinal fluid antibodies detect brain antigens.- 6 Immune complexes and the complement factors C4 and C3 in cerebrospinal fluid and serum from patients with multiple sclerosis.- 7 Characterization of circulating immunocomplexes in multiple sclerosis.- 8 Immunoelectrophoretic characterization of immune complexes from CSF of multiple sclerosis patients.- 9 Neurosurgery in the rehabilitation of hyperspasmodic and painful paraplegia in multiple sclerosis. Functional results in selective posterior rhizotomy.- 10 Immunological aspects of multiple sclerosis.- 11 Myelin basic protein and its antibodies in the cerebrospinal fluid in experimental allergic encephalopyelitis, multiple sclerosis and other diseases.- 12 Identification of myelin basic protein (MBP) as an antigenic component of circulating immune complexes (CIC) in MS patients.- 13 Sensitization of cerebrospinal fluid and peripheral blood lymphocytes to brain glycolipids in multiple sclerosis.- 14 Interferon production and natural killer (NK) activity in multiple sclerosis.- 15 ?-Albumin in cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases - comparison with other brain specific proteins.- 16 The Transferrin-Tau ratio of the CSF.- 17 Auto-antibodies to brain specific proteins.- 18 The effect of monoclonal anti-T cell antibodies on the clinical course of experimental allergic encephalomyelitis in rats.- 19 Changes of polymorphonuclear neutral proteinase activity in multiple sclerosis patients before and after plasma exchanges.- 20 Acid phosphatase activity of cerebrospinal fluid cells in multiple sclerosis and related neurological disorders.- 21 Influence of human allergic encephalitogenic peptide on platelet aggregation in multiple sclerosis.- 22 The effect of dietary supplementation of enriched marine oil on serum levels of ?-3 and ?-6 polyunsaturated fatty acids in multiple sclerosis.- Section II Treatment of the Disease.- 23 Immunological treatments in multiple sclerosis.- 24 Multiple sclerosis incidence material data used in the design of clinical trials.- 25 Long-term treatment with azathioprine in multiple sclerosis patients.- 26 Long-term immunotherapy in MS.- 27 Immunosuppression with cyclophosphamide in multiple sclerosis.- 28 Treatment of progressive multiple sclerosis by the combined application of antilymphocyte serum, azathioprine and prednisone.- 29 Clinical trials of a synthetic polypeptide (copolymer 1) for the treatment of multiple sclerosis.- 30 Lympho-plasmapheresis in multiple sclerosis: effect on clinical and immunological parameters.- 31 Plasmapheresis in multiple sclerosis: cerebrospinal fluid changes after treatment.- 32 Transfer factor treatment in multiple sclerosis: a 3 year prospective double-blind study (1982-1985).- 33 Experiences with immunoglobulin-G infusions in the treatment of acute multiple sclerosis.- 34 Dietary supplementation with polyunsaturated fatty acids in acute remitting multiple sclerosis.- 35 Essential fatty acids in the serum and cerebrospinal fluid of multiple sclerosis patients.- 36 The effect of large dose prednisone therapy on intrathecal IgG production in multiple sclerosis.- 37 Changes in T-cell subsets according to the course of MS and immunosuppressive treatment.- 38 T-lymphocyte subsets in the CSF in various stages of MS.- Section III Spinal Cord Dysfunctions in Multiple Sclerosis.- 39 Clinical and paraclinical assessment of spinal cord dysfunction.- 40 Functional testing of the spinal cord.- 41. Increased flexor reflex and spastic contracture in flexion; mechanisms and management.- 42 Tizanidine, a new antispastic agent: 6 years clinical experience in 152 MS patients.- 43 Objective assessment of the myorelaxant properties of tizanidine.- 44 Is electrical stimulation of the spinal cord useful in MS patients?.- Section IV Monitoring of the Disease.- 45 A silica gel radioimmunoassay determination of cerebrospinal fluid myelin basic protein levels of various demyelinating disease syndromes associated with multiple sclerosis.- 46 T-lymphocyte subpopulations in patients with MS: a study of 84 cases.- 47 Multiple sclerosis cerebrospinal fluid lymphocytes secretion in vitro: effect on myelinated cultures.- 48 Isotopic cisternography in multiple sclerosis: possible correlations with disease course.- 49 Management of acute multiple sclerosis by a long acting intrathecals administered corticosteroid.- 50 Diagnostic value of ?2-macroglobulin crossed immunoelectrophoresis in multiple sclerosis.- 51 The IgG index and the diagnosis of MS: a Bayesian approach.- 52 Neuro-urological problems in MS: diagnosis and treatment.- Section V Ophthalmological Aspects of Multiple Sclerosis.- 53 Central nervous system involvement in clinically pure optic neuritis (a pilot study in 25 patients).- 54 Prognostic value of CSF IgG in monosymptomatic optic neuritis..- 55 Cerebrospinal fluid findings in isolated optic neuritis compared to multiple sclerosis.- 56 Ophthalmological manifestations in multiple sclerosis: a statistical review of 1728 cases (1180 confirmed cases).- 57 Flight of colours-test in MS and NRB patients.- 58 The early diagnostic yield of multimodality evoked potentials: a 4.8 year prospective study on 171 patients.- 59 Effect of heating on VER of multiple sclerosis patients apparently free of optic neuritis.- Section VI Free Communications.- 60 Multiple sclerosis: a case-control study. A preliminary report.- 61 Numerical classification of multiple sclerosis.- 62 HLA-determination in twins with multiple sclerosis.- 63 Multiple sclerosis and myasthenia gravis.- 64 Intellectual impairment in multiple sclerosis.- 65 Multiple sclerosis: a conceptual reappraisal.- 66 A rarely reported multifocal demyelinating disease: pancreatic encephalopathy.- 67 Plaques, necrotic myelopathy and Rosenthal fibre reaction: glial pathology in MS.- 68 Comments on MS-compensation in West Germany.- 69 Multiple sclerosis and CT: a correlative study - preliminary results (43 cases).- 70 Multiple sclerosis and CT: a correlative study - preliminary results (39 cases).- 71 Multiple sclerosis: some preliminary findings of a neurological and medical-sociological prospective research project.- Section VII Posters.- P1 Measles antibodies, anti-proteinase and plasminogen distribution in serum and plasma from patients affected with multiple sclerosis and patients affected with non-neurological disease.- P2 The benign form of multiple sclerosis.- P3 Optic neuritis: laboratory tests for diagnosis and prognosis for the development of multiple sclerosis.- P4 Detection of S-100 protein in the cerebrospinal fluid of animals with acute experimental allergic encephalomyelitis.- P5 Estimation of levels of IgG to multiple sclerosis specific brain antigens in the cerebrospinal fluid of MS patients.- P6 Increased T-helper cell levels in cerebrospinal fluid.- P7 Laboratory test for hyperactivity (HA) in children: is childhood HA related to multiple sclerosis?.- P8 Isoelectric focusing on the CSF gamma-globulins in 2594 patients.- P9 Modulation of immunity in multiple sclerosis: a double-blind levamisole-placebo controlled study in 85 patients.- P10 Brain antigens detected by cerebrospinal fluid from multiple sclerosis patients.- P11 Cell-mediated immunity in progressive forms of multiple sclerosis treated by lympho-plasmapheresis.- P12 Myelin basic protein in cerebrospinal fluid, detected by an enzyme-immunoassay, and its diagnostic value.- P13 Onset-related values of serotonin, ceruloplasmin and 5-HIAA in patients with MS.- P14 Visual evoked potentials: a contribution in the assessment of multiple sclerosis.- P15 Shared antibrain specificities of cerebrospinal fluid and synovial fluid antibodies.- P16 Eye movement disorders in multiple sclerosis and optic neuritis.- P17 Do venous refluxes hurt the brain in MS? The fundamental problem.- P18 Blood-CSF barrier permselectivity and measurement of intrathecal IgG synthesis in multiple sclerosis.- P19 Azathioprine vs. transfer factor in multiple sclerosis patients: preliminary data.- P20 Epidemiology of multiple sclerosis in Italy. A further descriptive study in Barbagia, Sardinia.- P21 Antibrain antibody adsorption on microtitre plates.- P22 Search for viral nucleic acid sequences in the human central nervous systems.- P23 Ultrastructural study of virus-like particles in an acute case of multiple sclerosis.- Author index.